BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer
Nicolas Epaillard, Audrey Simonaggio, Réza Elaidi, Fouzia Azzouz, E. Braychenko, Constance Thibault, Cheng‐Ming Sun, Marco Moreira, Stéphane Oudard, Yann Vano
Topics & Concepts
NivolumabIpilimumabMedicineSunitinibRenal cell carcinomaOncologyPazopanibInternal medicineTyrosine-kinase inhibitorKidney cancerBiomarkerCancerImmunotherapyBiologyBiochemistryRenal cell carcinoma treatmentCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis